| Literature DB >> 28011413 |
Omolbanin Amjadi1, Alireza Rafiei2, Mohammadreza Haghshenas3, Reza Alizadeh Navaei1, Reza Valadan1, Zahra Hosseini-Khah4, Akbar Hedayatizadeh Omran5, Mohsen Arabi6, Reza Jafari Shakib7, Tahoora Mousavi1, G Hossein Ashrafi8.
Abstract
Varicella zoster virus (VZV) causes chicken pox as a primary infection following which it becomes latent in neurons. It may then reactivate to cause shingles (herpes zoster). Severity of lesions and VZV pathogenicity are depended on the host's immune response and variant in VZV Dr Athina Myrto ChioniIdentification of VZV seroprevalance rate in general population may lead to develop new health strategic managements such as vaccination. Therefore, we aimed to provide a systematic review of the seroprevalence of VZV infection among Iranian population and estimate age- and gender- specific prevalence of VZV. Keywords "seroprevalence"; "varicella zoster virus" and "Iran"; were searched in international electronic databases and also in national Persian databases. Twenty two pooled studies among 262 total studies containing (240 published articles; 18 dissertations; and 4 proceedings abstracts) from 1992 to 2014 with total sample size of 7867 individuals were included in the final review. Data was analyzed using random effect method. The heterogeneity was calculated using I-square statistics The overall IgG seroprevalence rate of VZV infection in general population of Iran was 78.50% (95% CI; 77.74%-79.25%). There was significant heterogeneity among the studies (P<0.0001; I2=99.4%). Furthermore, the relative risk of VZV infection is high in females (80.47%, 95% CI; 79.40%-81.54%) and older adults (95.30%, 95% CI; 94.11% -96.48%). Our results may represent a true background and estimation of VZV infection in Iran and generate the cost-benefits immunization program. Moreover, the ensuing data suggests further attention on disease seroprevalence in order to obtain efficient data for therapeutic intervention targeted against VZV.Entities:
Keywords: IgG; Immunity; Iran; Seroprevalence; Vaccination; Varicella zoster virus
Mesh:
Substances:
Year: 2016 PMID: 28011413 DOI: 10.1016/j.jcv.2016.12.001
Source DB: PubMed Journal: J Clin Virol ISSN: 1386-6532 Impact factor: 3.168